Applications of indocyanine green in robotic urology

Anthony S. Bates¹,² · Vipul R. Patel³

Abstract
Indocyanine green is a fluorescent molecule with wide ranging applications in minimally invasive urological surgery. This article explores the utility of ICG assisted intraoperative fluorescence in robotic urology.

Keywords
Indocyanine green · Robotic urology · RAPN · RARP · Intraoperative imaging · ICG · Da vinci

Indocyanine green (ICG) is a fluorescent molecule [1]. Incident infrared light of wavelength 780 nm provokes detectable photon emission at 820–830 nm [1]. Alongside a high definition camera and software imposed pseudo-colour, intravenously delivered ICG may be used to identify vessel perfusion and differentiate tissue density [2–4]. Indocyanine green was initially developed in the 1955 by Kodak photography, and received FDA approval in 1959 [5, 6]. Indocyanine green has a favourable safety profile, with an adverse event rate of 0.34 % including nausea, vomiting, and rarely shock (1 in 300,000) [7]. The use of ICG is established in ophthalmology, dermatology, and cardiology for vascular identification [8, 9]. This article will summarise the current and future applications of ICG in robotic urology, with the da Vinci® robot (dVSS), (Intuitive Surgical Systems, Sunnyvale, CA, USA) with emphasis placed on the intraoperative identification of vascular and oncological tissue. Notably, ICG is a cheap consumable, and infrared endoscopic equipment is widely available in contemporary dVSS systems (Firefly® in the DaVinci Xi).

A historical perspective of intraoperative imaging with fluorescent dye is necessary to describe intra-operative imaging advances from the 20th century applicable to modern robotic surgery. In 1947, seminal work was conducted by neurosurgeon George Moore at the University of Minnesota Medical School. Moore described the use of fluorescein, a fluorophore, to identify intracranial neoplastic tissue in the journal Science [10]. By 1948, Moore had performed a case series of 46 patients with mixed intracranial tumours [11]. Intraoperatively, he injected tumour with dye, identifying 44 tumours (96 %) correctly as malignant [11]. Moore went so far as to describe resection of remaining tissue based on fluorescent activity, thereby intraoperatively resecting positive surgical margins [11]. He also radiolabelled diiodofluorescein with iodine isotope 131 to detect gamma radiation from the accumulation of dye at malignant tissue [11].

Complex pelvic surgery has been revolutionised by the dVSS [12]. Wide adoption of the dVSS for radical prostatectomy and partial nephrectomy has followed, due to enhanced degrees of movement from the robotic wrist, tremor reduction, enhanced ergonomics, greater magnification, and the ability to operate in a closed anatomical space. Improved surgical recovery has been realised due to the minimal access approach, reductions in blood loss and a favourable learning curve, compared with the conventional laparoscopic technique [13–15]. Robotic outcomes are comparable to laparoscopic approaches and superior to open techniques [13–15]. Clinician and patient preference for use of the dVSS in performing robotic partial nephrectomy and prostatectomy are reflected clearly in the increasing caseload undertaken using the platform, with hundreds of centres now offering robotic prostatectomy worldwide [16]. Despite advances in robotics such as...
virtual reality simulation and adaptations to instruments, the basic configuration of the dVSS has remained relatively unchanged. Image guided surgery is well established in urology, such as x-ray guided fluoroscopic investigation of the urethra, bladder, ureter and reno-ureteric junction [17]. The combination of fluorescent intraoperative imaging and robotic surgery is a logical progression in peri-operative tissue visualisation. The fusion of minimally invasive surgery and localised imaging has been described in the identification of sentinel lymph nodes and renal cancer [18, 19], super selective arterial clamping for nephron sparing [20], and precise dissection of the prostatic neurovascular bundle [21].

In healthy renal parenchyma the transporter bilirubin transferase binds ICG and healthy tissue appears isofluorescent when perfused with ICG laden blood [22]. Renal tumour is deficient in bilirubin transferase and therefore appears hypofluorescent [19]. Tobis et al. noted hypofluorescent renal tumours in the presence of ICG during robotic partial nephrectomy (RAPN). The investigators were guided by ICG in selective arterial clamping of a handful of cases. Following this, Manny et al. subsequently calculated hypofluorescent tissue had a sensitivity of 84 % and positive predictive value of 87 % for malignant renal lesions in 100 RAPN cases [23]. Borofsky et al. then described superior selective renal artery clamping in 27 patients undergoing partial nephrectomy, with ICG, thus avoiding clamps to healthy renal parenchyma. Maximal loss of eGFR at 3 month follow-up was 1.6 versus 14.0 % in the non-ICG study arm [24]. Bjurlin et al. also reported a comparatively favourable 6.2 % decrease in glomerular filtration rate at 2 weeks postoperatively through the use of super-selective arterial clamping assisted with ICG [20, 25]. Patients undergoing super selective clamping showed significantly improved renal function at follow-up, however, these studies were underpowered and did not examine the impact of the technology upon intraoperative decision making [25].

Robot-assisted radical prostatectomy (RARP) may be supplemented by ICG imaging to identify the prostatic neurovascular bundle. In 2015, Patel et al. at demonstrated 30 % of prostatic neurovascular dissections were revised during nerve sparing RARP [21]. Given the degree of nerve spare correlates to functional outcomes [26], ICG holds promise for improving post-prostatectomy continence and erectile function. Robot-assisted sentinel node harvest is performed at RARP to determine metastatic nodal status. A hybrid fluorescent ICG radiotracer was optimised to detect sentinel lymph nodes in robot-assisted lymph node dissection, and improved in vivo identification through fluorescence to 93.5 % versus 50.0 % in non-optimised samples (n = 38; p = 0.005) [18]. In another series, robotic ICG assisted sentinel node harvest during RARP yielded a sensitivity of 100 % and negative predictive value of 100 % (n = 50), however, this method was non-specific. With larger sample sizes, it is likely the diagnostic coefficients would fall to below 100 % [27]. In spite of this, the potential utility of ICG for metastatic node detection and differentiation of oncological tissue remains encouraging.

Early work by Moore in revising surgical margins based on fluorescence, and the radiolabelling of fluorescent dye to localise oncological tissue was visionary. Recent technological advances in cancer biomarkers and immunology have prompted the hybridisation of ICG with cancer selective ligands, to localise tumour by fluorescence. Prostate specific membrane antigen (PSMA) is upregulated in prostate cancer by 100 to 1000-fold [28, 29]. Although at the pre-clinical stage, ICG bound PSMA-ligand was demonstrated to detect PSMA positive prostatic tumours in mice by Nakajima et al. using the humanised monoclonal antibody specific to PSMA, J591 [30]. Notably the J591 antibody has been delivered in several human clinical trials at high doses with a favourable safety profile [31–33]. In mice with human cell line prostate cancer, tumour was visually identifiable through fluorescence from 1 to 10 days after administration [30]. The accurate identification of previously indiscernible cancer tissue should be expected to transform positive surgical margin rates, and delay biochemical recurrence in prostate cancer. Similar advances in renal and bladder cancer immunology may also allow transfer of the technology to treat these pathologies.

In summary ICG combined with the dVSS is an incumbent game changer, and has been described as a “hammer looking for a nail” [25]. Evidence is emerging that ICG is useful in the robotic surgeon’s arsenal and yields tangible clinical benefit from selective arterial clamping in RAPN. Well-designed randomised controlled trials are urgently needed to quantify improvements in outcomes following ICG-augmented robotic procedures such as sentinel node excision, and identification of oncological tissue. It remains to be proven whether ICG brings small, incremental procedure-specific advances, or clinically substantial benefits to overall survival and functional recovery to these procedures. A revolutionary step in operative imaging though the labelling of fluorescent molecules to enhance en bloc tumour resection was espoused nearly 70 years ago by neurosurgeon Dr George Moore. Although at the pre-clinical stage, it is only a matter of time before Moore’s pioneering work is assimilated into routine robotic surgical practice.

Compliance with ethical standards

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Lansdown ML, Kwant G, Mook GA, Zijlstra WG (1976) Light-absorbing properties, stability, and spectral stabilization of indocyanine green. J Appl Physiol 40(4):575–583

2. Choi M, Choi K, Ryu SW, Lee J, Choi C (2011) Dynamic fluorescence imaging for multiparametric measurement of tumor vasculature. J Biomed Opt 16(4):046008

3. Sevick-Muraca EM, Houston JP, Gurfinkel M (2002) Fluorescence-enhanced, near infrared diagnostic imaging with contrast agents. Curr Opin Chem Biol 6(5):642–650

4. Schaalma BE, Mieog JD, Hutteman M et al (2011) The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 104(3):323–332

5. Brooker LGS, Heseltine DW, Inventors. Eastman Kodak Co, assignee (1959) Tricarbocyanine infrared absorbing dyes. United States Patent 289955A

6. United States Food and Drug Administration. Approval of “ICG-Green”. [Online]. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 10 April 2016

7. Obana A, Miki T, Hayashi K, Takeda M et al (1994) Survey of complications of indocyanine green angiography in Japan. Am J Ophthalmol 116(6):749–753

8. Alander JT, Kaartinen I, Laakso A et al (2012) A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging 2012:940585

9. Boni L, David G, Mangano A et al (2015) Clinical applications of indocyanine green (ICG) enhanced fluorescence in laparoscopic surgery. Surg Endosc 29(7):2046–2055

10. Moore GE (1947) Fluorescein as an Agent in the Differentiation of Normal and Malignant Tissues. Science 106(2745):130–131

11. Moore GE, Peyton WT, French LA, Walker WW (1948) The Clinical Use of Fluorescein in Neurosurgery. J Neurosurg 5(4):392–398

12. Morris B (2005) Robotic surgery: applications, limitations, and impact on surgical education. Med Gen Med 7(3):72

13. Novara G, Ficarra V, Moccellina S et al (2012) Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 62(3):382–404

14. Ficarra V, Novara G, Rosen RC et al (2012) Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62(3):405–417

15. Ficarra V, Novara G, Ahlering TE et al (2012) Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 62(3):418–430

16. Cathcart P, Nossiter J, Aggarwal A et al (2013) The first national clinical audit of prostate cancer care. BJU Int 112(7):883–884

17. Das CI, Balyan V, Sharma S (2015) Image-guided urological interventions: What are the urologists must know. Indian J Urol 31(3):202–208

18. KleinJan GH, van den Berg NS, Brouwer OR et al (2014) Optimisation of fluorescence guidance during robot-assisted laparoscopic sentinel node biopsy for prostate cancer. Eur Urol 66(6):991–998

19. Tobis S, Knop J, Silvers C et al (2011) Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors. J Urol 186(1):47–52

20. Bjurlin MA, Gan M, McClintock TR et al (2014) Near-infrared fluorescence imaging: emerging applications in robotic upper urinary tract surgery. Eur Urol 65(4):793–801

21. Kumar A, Samavedi S, Bates A et al (2015) Use of intra-operative indocyanine green and Firefly® technology to visualize the “landmark artery” for nerve sparing robot assisted radical prostatectomy. Eur Urol Suppl 2(14):eV36

22. Golijanian DJ, Marshall J, Cardin A et al (2008) Bilirubin translocase (BTL) is immunolocalised in proximal and distal renal tubules and absent in renal cortical tumors accurately corresponding to intraoperative near infrared fluorescence (NIRF) expression of renal cortical tumors using intravenous indocyanine green (ICG). J Urol 179(4):137

23. Mann TB, Krane LS, Hemal AK (2013) Indocyanine green cannot predict malignancy in partial nephrectomy: histopathologic correlation with fluorescence pattern in 100 patients. J Endourol 27(7):918–921

24. Borofsky MS, Gill IS, Hemal AK et al (2013) Near-infrared fluorescence imaging to facilitate super-selective arterial clamping during zero-ischaemia robotic partial nephrectomy. BJU Int 111(4):604–610

25. Krane LS, Hemal AK (2014) Surgery: Is indocyanine green dye useful in robotic surgery? Nat Rev Urol 11(1):12–14

26. Kang SG, Schatloff O, Haider AM et al (2015) Does surgeon subjective nerve sparing score predict recovery time of erectile function following robot-assisted radical prostatectomy? J Sex Med 12(6):1490–1496

27. Mann TB, Patel M, Hemal AK (2014) Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green: the initial clinical experience in 50 patients. Eur Urol 65(6):1162–1168

28. Montironi R, Lopez-Beltran A, Cheng L, Words of wisdom (2014) Re: Antibody-drug conjugates targeting prostate-specific membrane antigen. Eur Urol 66(6):1190–1193

29. Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91(3):528–539

30. Nakajima T, Mitsuogama M, Bander NH, Heston WD, Choyke PL, Kobayashi H (2011) Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody–indocyanine green (ICG) conjugate. Bioconjugate Chem 22(8):1700–1705

31. Bander NH, Milosky MI, Namus DM, Kostakoglu L, Vallabjajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21):4591–4601

32. Bander NH, Trabulsli EJ, Kostakoglu L et al (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170(5):1717–1721

33. Pandit-Taskar N, O’Donoghue JA, Beylergil V et al (2014) 89Zr-labeled J591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 41(11):2093–2105